The interesting work of Zhao et al,1 in the June issue of the journal, recommends the use of a patient-tailored dosing regimen in an attempt to optimise continuous-infusion vancomycin (CIV) therapy in the newborn population.

Despite the increasing use of CIV therapy during the past 10 years in neonates and young infants, the data on pharmacokinetics and dosing regimen of this drug are significantly lacking. Zhao et al1 chose to investigate the results of vancomycin therapeutic drug monitoring under three different regimens and to develop an optimised dosing model with the aim to decrease the number of off-target vancomycin …